These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25744849)

  • 1. Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis.
    McKee C; Sigala B; Soeda J; Mouralidarane A; Morgan M; Mazzoccoli G; Rappa F; Cappello F; Cabibi D; Pazienza V; Selden C; Roskams T; Vinciguerra M; Oben JA
    Sci Rep; 2015 Mar; 5():8812. PubMed ID: 25744849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcholine induces fibrogenic effects via M2/M3 acetylcholine receptors in non-alcoholic steatohepatitis and in primary human hepatic stellate cells.
    Morgan ML; Sigala B; Soeda J; Cordero P; Nguyen V; McKee C; Mouraliderane A; Vinciguerra M; Oben JA
    J Gastroenterol Hepatol; 2016 Feb; 31(2):475-83. PubMed ID: 26270240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells.
    Sigala B; McKee C; Soeda J; Pazienza V; Morgan M; Lin CI; Selden C; Vander Borght S; Mazzoccoli G; Roskams T; Vinciguerra M; Oben JA
    PLoS One; 2013; 8(9):e72928. PubMed ID: 24019886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotine induces fibrogenic changes in human liver via nicotinic acetylcholine receptors expressed on hepatic stellate cells.
    Soeda J; Morgan M; McKee C; Mouralidarane A; Lin C; Roskams T; Oben JA
    Biochem Biophys Res Commun; 2012 Jan; 417(1):17-22. PubMed ID: 22108052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
    Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
    Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
    Coombes JD; Choi SS; Swiderska-Syn M; Manka P; Reid DT; Palma E; Briones-Orta MA; Xie G; Younis R; Kitamura N; Della Peruta M; Bitencourt S; Dollé L; Oo YH; Mi Z; Kuo PC; Williams R; Chokshi S; Canbay A; Claridge LC; Eksteen B; Diehl AM; Syn WK
    Biochim Biophys Acta; 2016 Jan; 1862(1):135-44. PubMed ID: 26529285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-associated Steatohepatitis Development.
    Dashek RJ; Cunningham RP; Taylor CL; Alessi I; Diaz C; Meers GM; Wheeler AA; Ibdah JA; Parks EJ; Yoshida T; Chandrasekar B; Rector RS
    Cell Mol Gastroenterol Hepatol; 2024; 18(3):101365. PubMed ID: 38797477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH.
    Zanieri F; Levi A; Montefusco D; Longato L; De Chiara F; Frenguelli L; Omenetti S; Andreola F; Luong TV; Massey V; Caballeria J; Fondevila C; Shanmugavelandy SS; Fox T; Mazza G; Argemi J; Bataller R; Cowart LA; Kester M; Pinzani M; Rombouts K
    Cells; 2020 May; 9(5):. PubMed ID: 32429478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro.
    Böttcher K; Longato L; Marrone G; Mazza G; Ghemtio L; Hall A; Luong TV; Caruso S; Viollet B; Zucman-Rossi J; Pinzani M; Rombouts K
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G543-G556. PubMed ID: 33406006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.
    Jiang JX; Chen X; Fukada H; Serizawa N; Devaraj S; Török NJ
    Hepatology; 2013 Oct; 58(4):1339-48. PubMed ID: 23703665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K/AKT and ERK pathways.
    Zhang F; Zhang Z; Kong D; Zhang X; Chen L; Zhu X; Lu Y; Zheng S
    Mol Cell Endocrinol; 2014 Jan; 382(1):197-204. PubMed ID: 24071517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
    Kimura T; Singh S; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).
    Hada N; Katsume A; Kenichi K; Endo C; Horiba N; Sudoh M
    Pharmacol Res Perspect; 2023 Jun; 11(3):e01094. PubMed ID: 37204099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
    Arndt S; Wacker E; Dorn C; Koch A; Saugspier M; Thasler WE; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2015 Jun; 64(6):973-81. PubMed ID: 25011936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.